A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

519

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

February 29, 2012

Conditions
Breast Cancer
Interventions
DRUG

gemcitabine/carboplatin

"Gemcitabine 1000 mg/m2 intravenous infusion (30 ± 10 minutes)~Carboplatin AUC 2 intravenous infusion (30 ± 10 minutes or 60 ± 10 minutes)"

DRUG

Iniparib

"Body weight adjusted dose~intravenous infusion (60 ± 10 minutes)"

Trial Locations (102)

Unknown

Research Site, Birmingham

Research Site, Sedona

Research Site, Jonesboro

Research Site, Alhambra

Research Site, Bakersfield

Research Site, Campbell

Research Site, Fullerton

Research Site, Lancaster

Research Site, Long Beach

Research Site, Los Angeles

Research Site, Nothridge

Research Site, Oxnard

Research Site, Palo Alto

Research Site, Pomona

Research Site, Redondo Beach

Research Site, San Francisco

Research Site, Santa Barbara

Research Site, Santa Maria

Research Site, Sylmar

Research Site, Vallejo

Research Site, Westlake Village

Research Site, Whittier

Research Site, Denver

Research Site, Grand Junction

Research Site, Washington D.C.

Research Site, Bonita Springs

Research Site, Gainesville

Research Site, Hollywood

Research Site, Jacksonville

Research Site, Miami

Research Site, Ocala

Research Site, Ocoee

Research Site, Orange Park

Research Site, Orlando

Research Site, Port Saint Lucie

Research Site, Albany

Research Site, Athens

Research Site, Atlanta

Research Site, Augusta

Research Site, Lawrenceville

Research Site, Macon

Research Site, Marietta

Research Site, Savannah

Research Site, Coeur d'Alene

Research Site, Chicago

Research Site, Indianapolis

Research Site, Overland Park

Research Site, Westwood

Research Site, Baltimore

Research Site, Chevy Chase

Research Site, Westminster

Research Site, Boston

Research Site, Ann Arbor

Research Site, Royal

Research Site, Minneapolis

Research Site, Rochester

Research Site, Jackson

Research Site, Columbia

Research Site, St Louis

Reserach Site, Billings

Research Site, Grand Island

Research Site, Las Vegas

Research Site, Hooksett

Research Site, Morristown

Research Site, Sparta

Research Site, Santa Fe

Research Site, Amsterdam

Research Site, East Setauket

Research Site, New York

Research Site, Chapel Hill

Research Site, Charlotte

Research Site, Durham

Reserach Site, Durham

Research Site, Greensboro

Research Site, Raleigh

Research Site, Winston-Salem

Research Site, Cincinnati

Research Site, Toledo

Research Site, Portland

Research Site, Philadelphia

Research Site, Pittsburgh

Reserach Site, Columbia

Research Site, Chattanooga

Research Site, Memphis

Research Site, Nashville

Research Site, Austin

Research Site, Bedford

Research Site, Dallas

Research Site, Fort Worth

Research Site, Fredericksburg

Research Site, Houston

Research Site, Tyler

Research Site, Salt Lake City

Research Site, Fairfax

Research Site, Norfolk

Research Site, Richmond

Research Site, Roanoke

Research Site, Suffolk

Research Site, Kennewick

Research Sites, Seattle

Research Site, Vancouver

Research Site, Yakima

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00938652 - A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter